Skip to main content
Premium Trial:

Request an Annual Quote

NIH Awards Carnegie Mellon, University of Pittsburgh $13.3M to Create Center for Network, Pathway Technology

NEW YORK, April 24 (GenomeWeb News) - The National Institutes of Health has awarded a team of researchers from Carnegie Mellon University and the University of Pittsburgh a five-year grant worth $13.3 million to establish a National Technology Center for Networks and Pathways.


The center will focus on developing fluorescent probe and imaging technologies to investigate regulatory pathways and networks in real time in living cells, according to Carnegie Mellon. The university said the effort is expected to generate molecular biosensors for preclinical research to map the many cell-signaling networks involved in disease. In the future, the biosensors may be used in hospital- and office-based diagnostic medicine, it added.


Carnegie Mellon, which will house the new center, said that the grant is one of three awarded under the NIH's "Building Blocks, Biological Pathways and Networks Roadmap for Medical Research," an initiative aimed at supporting research to develop tools that determine in real time the amounts, locations, and interactions of large numbers of individual proteins within a single cell.

The Scan

Follow-Up Data Requests to Biobank Participants Ineffective, Study Finds

An effort to recontact biobank enrollees for additional information reports low participation in a new BMJ Open study.

Study Finds Widespread Transmission of Resistant Bacteria in Vietnam Hospitals

A sequencing study in The Lancet Microbe finds widespread transmission of drug-resistant Escherichia coli, Klebsiella pneumoniae, and Acinetobacter baumannii in two Vietnam ICUs.

Novel Brain Cell Organoids Show Promise for Autism Research

University of Utah researchers report in Nature Communications on their development of brain cell organoids to study SHANK3-related autism.

Study Finds Few FDA Post-Market Regulatory Actions Backed by Research, Public Assessments

A Yale University-led team examines in The BMJ safety signals from the US FDA Adverse Event Reporting System and whether they led to regulatory action.